UBS Asset Management Americas Inc. Takes Position in Aclaris Therapeutics, Inc. (ACRS)

UBS Asset Management Americas Inc. bought a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 110,037 shares of the biotechnology company’s stock, valued at approximately $2,984,000. UBS Asset Management Americas Inc. owned about 0.41% of Aclaris Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. New York State Common Retirement Fund boosted its position in shares of Aclaris Therapeutics by 85.1% in the second quarter. New York State Common Retirement Fund now owns 23,661 shares of the biotechnology company’s stock worth $642,000 after purchasing an additional 10,877 shares during the period. Westfield Capital Management Co. LP boosted its position in shares of Aclaris Therapeutics by 79.6% in the second quarter. Westfield Capital Management Co. LP now owns 1,249,254 shares of the biotechnology company’s stock worth $33,880,000 after purchasing an additional 553,752 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Aclaris Therapeutics by 26.0% in the second quarter. PNC Financial Services Group Inc. now owns 9,220 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 1,900 shares during the period. Nationwide Fund Advisors boosted its position in shares of Aclaris Therapeutics by 72.4% in the second quarter. Nationwide Fund Advisors now owns 11,423 shares of the biotechnology company’s stock worth $310,000 after purchasing an additional 4,796 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its position in shares of Aclaris Therapeutics by 20.6% in the second quarter. TIAA CREF Investment Management LLC now owns 214,941 shares of the biotechnology company’s stock worth $5,829,000 after purchasing an additional 36,667 shares during the period. 95.85% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “UBS Asset Management Americas Inc. Takes Position in Aclaris Therapeutics, Inc. (ACRS)” was first published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.thestockobserver.com/2017/10/13/ubs-asset-management-americas-inc-takes-position-in-aclaris-therapeutics-inc-acrs.html.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.12.

In related news, Director Andrew N. Schiff purchased 108,601 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The stock was bought at an average price of $23.02 per share, with a total value of $2,499,995.02. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 16.30% of the stock is currently owned by insiders.

A number of equities analysts have weighed in on ACRS shares. Cantor Fitzgerald started coverage on shares of Aclaris Therapeutics in a research report on Friday, June 16th. They issued an “overweight” rating and a $50.00 price target for the company. Jefferies Group LLC reiterated a “buy” rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a research report on Wednesday, June 28th. Guggenheim reiterated a “buy” rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a research report on Tuesday, July 4th. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a research report on Tuesday. Finally, ValuEngine upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Aclaris Therapeutics has an average rating of “Buy” and a consensus price target of $39.20.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply